---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-025293"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:38:41.397087+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coherus Oncology reports FY2025 net loss $183.1M; LOQTORZI revenue doubles to $40.8M

## Summary
- LOQTORZI net revenue $40.8M in 2025, more than double $19.1M in 2024; Q4 net revenue $12.4M up 11% QoQ.
- Total debt reduced 90% from $480M to $38.8M during 2024-2025; year-end cash $172.1M.
- FY2025 GAAP net loss $183.1M ($1.56 diluted) vs $215.4M loss in FY2024; non-GAAP loss $159.2M.
- Pipeline: tagmokitug (CCR8) trials in HNSCC, GI, ESCC, CRC; casdozokitug (IL-27) Phase 2 in 1L uHCC; data readouts in mid-2026.
- Equity financings: ~$7.9M net from Oct 2025 offering; ~$47.0M net from Feb 2026 public offering.

## SEC filing metadata
- accession: 0001104659-26-025293
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/0001104659-26-025293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/chrs-20260309x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-025293
- JSON: https://secwatch.observer/filing/0001104659-26-025293.json
- Plain text: https://secwatch.observer/filing/0001104659-26-025293.txt

## Key facts
- Earnings Releases
  Coherus Oncology, Inc. reported the years ended December 31, 2025 results: revenue $42.2 million.
  - Period: the years ended December 31, 2025
  - Revenue: $42.2 million
  - Result: reported results
  source text: Net revenue from continuing operations was $12.7 million and $7.7 million during the three months ended December 31, 2025 and 2024, respectively, and $42.2 million and $26.4 million during the years ended December 31, 2025 and 2024, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/0001104659-26-025293-index.htm
- Earnings Releases
  Coherus Oncology, Inc. reported the three months ended December 31, 2025 results: revenue $12.7 million.
  - Period: the three months ended December 31, 2025
  - Revenue: $12.7 million
  - Result: reported results
  source text: Net revenue from continuing operations was $12.7 million and $7.7 million during the three months ended December 31, 2025 and 2024, respectively, and $42.2 million and $26.4 million during the years ended December 31, 2025 and 2024, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/0001104659-26-025293-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.